TNNT1, troponin T1, slow skeletal type, 7138

N. diseases: 60; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis 		0.020 GeneticVariation disease BEFREE The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C. 29618599 2018
CUI: C0010054
Disease: Coronary Arteriosclerosis
Coronary Arteriosclerosis 		0.020 GeneticVariation disease BEFREE Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease. 26950807 2016
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease 		0.020 GeneticVariation disease BEFREE The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C. 29618599 2018
CUI: C0010068
Disease: Coronary heart disease
Coronary heart disease 		0.020 GeneticVariation disease BEFREE Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease. 26950807 2016
CUI: C0027126
Disease: Myotonic Dystrophy
Myotonic Dystrophy 		0.020 Biomarker disease BEFREE This work rules out a defect in the coding segment of TNNT1 as a cause of DM and provides a polymerase chain reaction protocol for studying troponin T gene expression. 1473264 1992
CUI: C0027126
Disease: Myotonic Dystrophy
Myotonic Dystrophy 		0.020 GeneticVariation disease BEFREE Sequence analysis confirmed that MSL 366 is the cDNA for human slow skeletal muscle troponin T. A genomic clone has been isolated and linkage studies with DM are in progress. 1706783 1990
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.020 GeneticVariation disease BEFREE The present post hoc analysis from TNT shows that increased TRL-C levels are associated with an increased cardiovascular risk and provides evidence for the cardiovascular benefit of lipid lowering with statins among patients who have coronary heart disease with high TRL-C. 29618599 2018
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease 		0.020 GeneticVariation disease BEFREE These results suggest that TNNT1 genetic and epigenetic variations are associated with HDL-C levels and CAD. 26950807 2016
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.020 Biomarker group BEFREE TNT, or systemic chemotherapy followed by chemoradiation (CRT), addresses both occult metastases and positive margin risks and thus is a potentially optimal strategy; however, factors predictive of perioperative and survival outcomes are currently undefined. 30946090 2019
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.020 AlteredExpression group BEFREE Genes overexpressed in LMS metastases included TNNT1, FOLR3, TDO2, CRYM, GJA1, TSPAN10, THBS1, SGK1, SHMT1, EGR2, and AGT. 24485798 2014
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.020 Biomarker disease BEFREE Importantly, the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following (neo)adjvuvant multi-agent chemotherapy, bevacizumab benefit in the neoadjuvant setting (CALGB40603), and docetaxel vs. carboplatin benefit in first-line metastatic disease (TNT study). 26253814 2015
CUI: C3539878
Disease: Triple Negative Breast Neoplasms
Triple Negative Breast Neoplasms 		0.020 GeneticVariation disease BEFREE Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 29713086 2018
CUI: C4722518
Disease: Triple-Negative Breast Carcinoma
Triple-Negative Breast Carcinoma 		0.020 GeneticVariation disease BEFREE Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 29713086 2018
CUI: C4722518
Disease: Triple-Negative Breast Carcinoma
Triple-Negative Breast Carcinoma 		0.020 Biomarker disease BEFREE Importantly, the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following (neo)adjvuvant multi-agent chemotherapy, bevacizumab benefit in the neoadjuvant setting (CALGB40603), and docetaxel vs. carboplatin benefit in first-line metastatic disease (TNT study). 26253814 2015
CUI: C0002986
Disease: Fabry Disease
Fabry Disease 		0.010 Biomarker disease BEFREE Hs-TNT and NT-proBNP levels were significantly higher in the CA group [median: hs-TNT 98 pg/mL, NT-proBNP 4,110 pg/mL] than in the FA group [hs-TNT 14 pg/mL, NT-proBNP 40 pg/mL] and FD group [hs-TNT 18 pg/mL, NT-proBNP 131 pg/mL, both P<0.001]. 30233871 2018
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 Biomarker disease BEFREE TNNT1 facilitates proliferation of breast cancer cells by promoting G<sub>1</sub>/S phase transition. 30031058 2018
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.010 AlteredExpression disease BEFREE Immunohistochemical staining and real-time PCR were used to compare the expression level of TNNT1 in CRC tissues and adjacent tissues. 31830337 2020
CUI: C0009917
Disease: Contracture
Contracture 		0.010 Biomarker disease BEFREE Our cases expand the mutational spectrum of TNNT1, confirm the invariable peculiar clinical phenotype also outside the Amish population, and suggest that TNNT1 should be considered for molecular analysis in NM patients with chest deformities and progressive contractures. 31604653 2019
CUI: C0015672
Disease: Fatigue
Fatigue 		0.010 Biomarker phenotype BEFREE Deficiency of slow skeletal muscle troponin T causes atrophy of type I slow fibres and decreases tolerance to fatigue. 24445317 2014
CUI: C0016719
Disease: Friedreich Ataxia
Friedreich Ataxia 		0.010 Biomarker disease BEFREE Hs-TNT and NT-proBNP levels were significantly higher in the CA group [median: hs-TNT 98 pg/mL, NT-proBNP 4,110 pg/mL] than in the FA group [hs-TNT 14 pg/mL, NT-proBNP 40 pg/mL] and FD group [hs-TNT 18 pg/mL, NT-proBNP 131 pg/mL, both P<0.001]. 30233871 2018
CUI: C0020445
Disease: Hypercholesterolemia, Familial
Hypercholesterolemia, Familial 		0.010 GeneticVariation disease BEFREE Patients, materials & methods: TNNT1 DNA methylation and c.-20G>A polymorphism were genotyped in subjects with and without familial hypercholesterolemia (FH). 26950807 2016
CUI: C0022660
Disease: Kidney Failure, Acute
Kidney Failure, Acute 		0.010 Biomarker disease BEFREE Two reviewers independently extracted data using a standardized data extraction protocol where TNI or TNT concentrations; total TNI released after cardiac surgery; and the incidence of AKI, AMI, and mortality were recorded. 29210794 2018
CUI: C0024117
Disease: Chronic Obstructive Airway Disease
Chronic Obstructive Airway Disease 		0.010 Biomarker disease BEFREE In conclusion, our findings indicated that TNNT1 may promote the progression of COAD, mediating EMT process, and thus shed a novel light on COAD therapeutic treatments. 31512553 2020
CUI: C0027868
Disease: Neuromuscular Diseases
Neuromuscular Diseases 		0.010 Biomarker group BEFREE Troponin T1 (TNNT1) is a subunit of troponin that has been linked to neuromuscular disorder. 31830337 2020
CUI: C0033860
Disease: Psoriasis
Psoriasis 		0.010 Biomarker disease BEFREE High-dose atorvastatin significantly reduced cardiovascular events vs. standard/low-dose statins in patients without psoriasis in TNT/IDEAL; similar numeric differences in event rates were observed in patients with psoriasis. 28573499 2017